WASHINGTON, United States (AFP) — Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday. Pfizer’s CEO Albert Bourla previously said at a conference that the pharmaceutical giant could be ready to file for regulatory approval of the shot by March. The company’s head of vaccine research Kathrin Jansen said […]